Arcellx, Inc. Quality Score

ACLX

⊜ Compare

Quality10

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Growth

Revenue Growth

0/100

-55.1%

Below 2%, essentially flat

Cash Flow Growth

0/100

Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution

0/100

17.2%

Heavy dilution above 5%

Margin Trend

0/100

-1054.1pp

Contracted >2pp, margin pressure

Capital Structure

100/100

-$398M

Net cash position, no leverage concern

2023

$702M

$98.0M

2024

$587M

$54.0M

2025

$450M

$52.0M

CashDebt

Return on Capital

0/100

-41.5%

Below 8%, may not cover cost of capital

Customize WeightsPremiumAdjust metric weights to match your investment style.Upgrade

SourceQuality score computed from the 10-Q filed 20 Feb 2026, covering the period ending 31 Dec 2025, as reported to the SEC. Data last refreshed 25 Sept 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with ACLX

CompareIntrinsic value

LENZLENZ Therapeutics, Inc.

$3.46-1.14%10

MGXMetagenomi, Inc.

$0.79+3.95%10

GLUEMonte Rosa Therapeutics, Inc.

$10.82+3.94%10

ACOGAlpha Cognition Inc.

$8.49+3.48%10

ALECAlector Inc.

$2.28+11.22%10

SCLXScilex Holding Company

$1.83-1.08%0

CRSPCrispr Therapeutics AG

$51.78+3.57%40

LCTXLineage Cell Therapeutics Inc.

$1.03+1.98%10

Spot a number that looks wrong? Check it in ACLX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ACLX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.